HUE049409T2 - Alkinilpiridin-prolil-hidroxiláz inhibitor és annak elõállítási eljárása és gyógyászati alkalmazása - Google Patents

Alkinilpiridin-prolil-hidroxiláz inhibitor és annak elõállítási eljárása és gyógyászati alkalmazása

Info

Publication number
HUE049409T2
HUE049409T2 HUE15905721A HUE15905721A HUE049409T2 HU E049409 T2 HUE049409 T2 HU E049409T2 HU E15905721 A HUE15905721 A HU E15905721A HU E15905721 A HUE15905721 A HU E15905721A HU E049409 T2 HUE049409 T2 HU E049409T2
Authority
HU
Hungary
Prior art keywords
preparation
medical use
prolyl hydroxylase
hydroxylase inhibitor
alkynyl pyridine
Prior art date
Application number
HUE15905721A
Other languages
English (en)
Inventor
Qidong You
Xiaojin Zhang
Yonghua Lei
Tianhan Hu
Xingsen Wu
Haopeng Sun
Xiaoke Guo
Xiaoli Xu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of HUE049409T2 publication Critical patent/HUE049409T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HUE15905721A 2015-10-09 2015-11-27 Alkinilpiridin-prolil-hidroxiláz inhibitor és annak elõállítási eljárása és gyógyászati alkalmazása HUE049409T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510648342.9A CN105130888A (zh) 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Publications (1)

Publication Number Publication Date
HUE049409T2 true HUE049409T2 (hu) 2020-10-28

Family

ID=54716523

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15905721A HUE049409T2 (hu) 2015-10-09 2015-11-27 Alkinilpiridin-prolil-hidroxiláz inhibitor és annak elõállítási eljárása és gyógyászati alkalmazása

Country Status (21)

Country Link
US (2) US10889546B2 (hu)
EP (1) EP3360862B1 (hu)
JP (1) JP6635562B2 (hu)
KR (1) KR20180063229A (hu)
CN (2) CN105130888A (hu)
AU (1) AU2015411258B2 (hu)
BR (1) BR112018005969A2 (hu)
CA (1) CA3000040A1 (hu)
DK (1) DK3360862T3 (hu)
ES (1) ES2794002T3 (hu)
HK (1) HK1247613A1 (hu)
HR (1) HRP20200907T1 (hu)
HU (1) HUE049409T2 (hu)
LT (1) LT3360862T (hu)
MX (1) MX2018003832A (hu)
PL (1) PL3360862T3 (hu)
PT (1) PT3360862T (hu)
RU (1) RU2692494C1 (hu)
SI (1) SI3360862T1 (hu)
UA (1) UA120407C2 (hu)
WO (1) WO2017059623A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105130888A (zh) 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN107417605A (zh) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 作用于脯氨酰羟化酶的吡啶衍生化合物
BR112020007499A2 (pt) * 2017-10-25 2020-10-06 Jiangsu Hengrui Medicine Co., Ltd. forma cristalina do inibidor de alquinil piridina prolil hidroxilase e processo para a preparação da mesma
CN110240562B (zh) * 2018-03-08 2022-04-12 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
JP2021523921A (ja) * 2018-05-24 2021-09-09 蘇州盛迪業生物医薬有限公司Suzhou Suncadia Biopharmaceuticals Co.,Ltd. アルキニルピリジンプロリルヒドロキシラーゼ阻害剤の製造方法
CN109593084B (zh) * 2019-01-23 2021-09-28 中国药科大学 脯氨酰羟化酶小分子光敏前药及其制备方法与应用
BR112021017188A2 (pt) * 2019-03-04 2021-11-09 Jiangsu Hengrui Medicine Co Composição farmacêutica de inibidor da prolil hidroxilase e método de preparação do mesmo
CN112741834A (zh) * 2021-02-07 2021-05-04 复旦大学附属中山医院 HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途
CN116514710B (zh) * 2022-01-21 2024-07-05 中国药科大学 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410480A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
HUE041300T2 (hu) * 2006-06-26 2019-05-28 Akebia Therapeutics Inc Prolilhidroxiláz inhibitorok és alkalmazási eljárások
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
TW201141839A (en) * 2010-04-19 2011-12-01 Daiichi Sankyo Co Ltd Substituted 5-hydroxypyrimidine-4-carboxamide compounds
US9738604B2 (en) * 2010-09-03 2017-08-22 Duke University Ethynylbenzene derivatives
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
CN105130888A (zh) 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Also Published As

Publication number Publication date
CN105130888A (zh) 2015-12-09
PL3360862T3 (pl) 2020-09-21
BR112018005969A2 (pt) 2018-10-16
CN107848976B (zh) 2020-11-17
AU2015411258B2 (en) 2020-09-17
HK1247613A1 (zh) 2018-09-28
US10889546B2 (en) 2021-01-12
EP3360862B1 (en) 2020-04-22
PT3360862T (pt) 2020-05-27
RU2692494C1 (ru) 2019-06-25
SI3360862T1 (sl) 2020-08-31
JP6635562B2 (ja) 2020-01-29
KR20180063229A (ko) 2018-06-11
HRP20200907T1 (hr) 2020-09-04
EP3360862A1 (en) 2018-08-15
UA120407C2 (uk) 2019-11-25
MX2018003832A (es) 2018-06-18
CA3000040A1 (en) 2017-04-13
US20200407319A1 (en) 2020-12-31
CN107848976A (zh) 2018-03-27
EP3360862A4 (en) 2018-08-15
JP2018529690A (ja) 2018-10-11
ES2794002T3 (es) 2020-11-17
WO2017059623A1 (zh) 2017-04-13
DK3360862T3 (da) 2020-06-02
AU2015411258A1 (en) 2018-05-10
LT3360862T (lt) 2020-07-10
US20180305317A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
HK1247613A1 (zh) 炔基吡啶類脯氨酰羥化酶抑制劑、其製備方法和醫藥用途
PT3546457T (pt) Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
HK1251551A1 (zh) 氮雜環丁烷衍生物、其製備方法及用途
IL259711A (en) Methods for the preparation of protein kinase inhibitors and their medical use
PL3181560T3 (pl) Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie
HK1244808A1 (zh) 苯並哌啶類衍生物、其製備方法及其在醫藥上的應用
EP3181744A4 (en) Treatment device and treatment method
EP3363348A4 (en) PHYSIOLOGICAL STATE DETERMINATION DEVICE AND PHYSIOLOGICAL STATE DETERMINING METHOD
EP3356976A4 (en) METHOD FOR ASSESSING THE NORMALITY OF AN IMMUNORE TERRE AND THE USE THEREOF
HK1243997B (zh) Kv1.3抑制劑及其醫學應用
ZA202002517B (en) Compounds and methods for reducing snca expression
GB201907083D0 (en) 99mtc-labelled isonitrile-containing glucose derivative and preparation method and use
SG11201800235RA (en) Patient status determination device, patient status determination method and program
EP3381919A4 (en) Substituted triazolopiperazine parp inhibitor, preparation method therefor, and use thereof
EP3299488A4 (en) Carburization device and carburization method
EP3381921A4 (en) GINKGOLIDE B DERIVATIVE AND METHOD OF PREPARING THEREOF AND USE THEREOF
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3253734A4 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
HK1243998A1 (zh) Kv1.3抑制劑及其醫學應用
EP3313488A4 (en) DEVICE AND METHOD FOR OXYGEN BIOFEEDBACK
EP3181177B8 (fr) Nécessaire de traitement, dispositif de mesure et utilisation associés